The International Academy of Compounding Pharmacists (IACP) joined hundreds of thousands of women and doctors in applauding the introduction of a resolution stating that “the Food and Drug Administration’s (FDA) new policy restricting women’s access to medications containing estriol does not serve the public interest” and calling on the FDA to “reverse its policy.”
The resolution follows the introduction of a similar measure in the U.S. House of Representatives in early May. IACP’s Executive Director L.D. King says, “women with menopause suffer enough. Fortunately, this resolution aims to provide them with some relief.”
The response from patients, doctors and pharmacists has been overwhelming. Since Oct. 2005, more than 70,000 patients, doctors and pharmacists have written to FDA opposing Wyeth’s petition. Since Jan. 2008, more than 10,000 have written to FDA opposing the agency’s new estriol policy. And since the first resolution was introduced in the House last month, more than 4,000 have written to Congress in strong support of the measure.
Compounded hormones containing estriol are lawfully prescribed, prepared and dispensed in all 50 states. The FDA has acknowledged that it is unaware of any adverse events associated with the use of these drugs.
Stay tuned .